| __timestamp | Amphastar Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 91733000 |
| Thursday, January 1, 2015 | 46974000 | 87644000 |
| Friday, January 1, 2016 | 47298000 | 92365000 |
| Sunday, January 1, 2017 | 50918000 | 85656000 |
| Monday, January 1, 2018 | 58044000 | 88196000 |
| Tuesday, January 1, 2019 | 63109000 | 89971000 |
| Wednesday, January 1, 2020 | 65157000 | 93413000 |
| Friday, January 1, 2021 | 68920000 | 91355000 |
| Saturday, January 1, 2022 | 66592000 | 113676000 |
| Sunday, January 1, 2023 | 80393000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Amphastar Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. have been navigating this financial landscape since 2014. Over the years, Taro has consistently maintained higher SG&A expenses, peaking at approximately $219 million in 2024, a staggering 172% increase from 2014. In contrast, Amphastar's expenses grew by about 99% over the same period, reaching around $80 million in 2023. This data suggests Taro's aggressive expansion strategy, while Amphastar appears more conservative. However, the absence of Amphastar's 2024 data leaves room for speculation. As these companies continue to evolve, their SG&A strategies will be pivotal in shaping their financial futures.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.